Massachusetts Eye and Ear Infirmary Report issue

Academic/Hospital Phase 1 Phase 4

Organization Overview

First Clinical Trial
2012
NCT01961297
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Faisal Karmali | Faisal_Karmali@MEEI.HARVARD.EDU | Joseph B. Ciolino, MD

Active Ingredients

Drugs in Phase 4 Trials (1)

promethazine hydrochloride (phenergan) (1 trial)

Drugs in Phase 1 Trials (1)

riboflavin (1 trial)

Drugs in Other Trials (1)

sodium oxybate (xyrem) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dysphonia (Phase 3)

Hoarseness (Phase 3)

Motion Sickness (Phase 4)

Space Motion Sickness (Phase 4)

Tremor (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 3